SG11201805888SA - Cyclic dinucleotides for treating conditions associated with sting activity such as cancer - Google Patents
Cyclic dinucleotides for treating conditions associated with sting activity such as cancerInfo
- Publication number
- SG11201805888SA SG11201805888SA SG11201805888SA SG11201805888SA SG11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cancer
- pct
- sting
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US201662436759P | 2016-12-20 | 2016-12-20 | |
| PCT/US2017/013066 WO2017123669A1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805888SA true SG11201805888SA (en) | 2018-08-30 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805888SA SG11201805888SA (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (pt) |
| EP (1) | EP3402801A1 (pt) |
| JP (1) | JP6867395B2 (pt) |
| KR (1) | KR20180097751A (pt) |
| CN (1) | CN109451740B (pt) |
| AU (1) | AU2017207757B2 (pt) |
| BR (1) | BR112018013808A2 (pt) |
| CA (1) | CA3011528A1 (pt) |
| CL (1) | CL2018001870A1 (pt) |
| CO (1) | CO2018008196A2 (pt) |
| EA (1) | EA036421B1 (pt) |
| IL (1) | IL260427B (pt) |
| MX (1) | MX2018008266A (pt) |
| MY (1) | MY194058A (pt) |
| PE (1) | PE20181330A1 (pt) |
| SG (1) | SG11201805888SA (pt) |
| WO (1) | WO2017123669A1 (pt) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| PE20181330A1 (es) * | 2016-01-11 | 2018-08-20 | Innate Tumor Immunity Inc | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer |
| WO2017161349A1 (en) | 2016-03-18 | 2017-09-21 | Immune Sensor, Llc | Cyclic di-nucleotide compounds and methods of use |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| AU2017293781B2 (en) | 2016-07-06 | 2022-12-22 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2018045058A1 (en) | 2016-08-30 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
| UA125223C2 (uk) | 2016-10-04 | 2022-02-02 | Мерк Шарп І Доум Корп. | СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| RU2020109328A (ru) | 2017-08-04 | 2021-09-06 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака |
| RU2020112502A (ru) | 2017-08-30 | 2021-10-01 | Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. | Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона |
| JP7316263B2 (ja) * | 2017-08-31 | 2023-07-27 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| KR20200100033A (ko) | 2017-09-14 | 2020-08-25 | 얀센 바이오파마, 인크. | 변형된 뉴클레오시드 포스포르아미다이트 |
| US11660311B2 (en) * | 2017-10-10 | 2023-05-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US11685761B2 (en) | 2017-12-20 | 2023-06-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019173587A1 (en) * | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| EP3768685A1 (en) | 2018-03-23 | 2021-01-27 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| EP3774765A4 (en) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| CA3095646A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11292812B2 (en) | 2018-04-06 | 2022-04-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotides |
| CA3101368A1 (en) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| BR112021001349A2 (pt) | 2018-08-16 | 2021-04-20 | Eisai R&D Management Co., Ltd. | sais de compostos e cristais dos mesmos |
| BR112021003472A2 (pt) | 2018-09-06 | 2021-05-18 | Daiichi Sankyo Company, Limited | derivado de dinucleotídeo cíclico e conjugado de anticorpo-fármaco do mesmo |
| AU2019339344A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
| AU2019344398B2 (en) | 2018-09-21 | 2022-09-22 | Shanghai De Novo Pharmatech Co., Ltd. | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| US20220064205A1 (en) * | 2018-12-04 | 2022-03-03 | Bristol-Myers Squibb Company | Process for the preparation of a cyclic dinucleotide |
| EP3921323A1 (en) * | 2019-02-05 | 2021-12-15 | Bristol-Myers Squibb Company | Synthesis of 1,2,5-tri-0-benz0yl-3-dibenzylamin0-3-de0xyrib0se as intermediate for producing 3'-amino-3'-deoxyadenosine and 3'-amino-3'-deoxyguanosine and the protected derivatives thereof |
| CN114173824A (zh) | 2019-05-10 | 2022-03-11 | 武田药品工业株式会社 | 抗体药物缀合物 |
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202114710A (zh) * | 2019-07-25 | 2021-04-16 | 英屬開曼群島商百濟神州有限公司 | 作為sting促效劑之環狀二核苷酸 |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| KR20220122701A (ko) | 2019-12-26 | 2022-09-02 | 내셔널 유니버시티 코포레이션 토카이 내셔널 하이어 에듀케이션 앤드 리서치 시스템 | 폴리뉴클레오티드 및 의약 조성물 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| MX2022009597A (es) | 2020-03-06 | 2022-09-02 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco que incluye derivado de dinucleotido ciclico novedoso. |
| KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
| EP4138852A4 (en) * | 2020-04-21 | 2024-05-15 | Univ Duke | COMPOSITIONS AND METHODS FOR TREATING PAIN |
| US20230226218A1 (en) | 2020-05-11 | 2023-07-20 | Erytech Pharma | Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof |
| TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| AU2021338014A1 (en) | 2020-09-02 | 2023-03-09 | Daiichi Sankyo Company, Limited | Novel endo-β-N-acetylglucosaminidase |
| KR20230088750A (ko) * | 2020-10-15 | 2023-06-20 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 면역 반응을 조절할 수 있는 금속 이온과 sting 작용제의 결정질 다형 형태 |
| KR102466750B1 (ko) * | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| EP4237012A1 (en) | 2020-10-30 | 2023-09-06 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
| WO2022097117A1 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Antibody drug conjugates |
| EP4365288A1 (en) | 2021-06-30 | 2024-05-08 | Kyowa Kirin Co., Ltd. | Polynucleotide and medicinal composition |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20050203061A1 (en) | 2002-06-20 | 2005-09-15 | Shinya Yamashita | Prodrug, medicinal utilization thereof and process for producing the same |
| EP1729781B1 (en) * | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| CA2876150A1 (en) | 2012-06-08 | 2013-12-12 | The Johns Hopkins University | Compostions and methods for cancer immunotherapy |
| BR112015013440B1 (pt) | 2012-12-13 | 2020-12-08 | Aduro Biotech, Inc | composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas |
| WO2014179335A1 (en) * | 2013-04-29 | 2014-11-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| EP3060056A4 (en) | 2013-10-21 | 2017-10-18 | Drexel University | Use of sting agonists to treat chronic hepatitis b virus infection |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| US20150144176A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| PE20170198A1 (es) | 2014-06-04 | 2017-04-08 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting |
| EP3546473A1 (en) | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| RU2020113165A (ru) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
| PE20181330A1 (es) * | 2016-01-11 | 2018-08-20 | Innate Tumor Immunity Inc | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer |
| WO2017161349A1 (en) | 2016-03-18 | 2017-09-21 | Immune Sensor, Llc | Cyclic di-nucleotide compounds and methods of use |
-
2017
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/es unknown
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/ja active Active
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/pt active Search and Examination
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
- 2017-01-11 EA EA201891565A patent/EA036421B1/ru not_active IP Right Cessation
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en active Application Filing
- 2017-01-11 EP EP17704338.7A patent/EP3402801A1/en active Pending
- 2017-01-11 KR KR1020187022863A patent/KR20180097751A/ko not_active Application Discontinuation
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/es unknown
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/zh active Active
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/es unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/es unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL260427B (en) | 2021-03-25 |
| BR112018013808A2 (pt) | 2018-12-11 |
| CO2018008196A2 (es) | 2018-08-10 |
| US20200165288A1 (en) | 2020-05-28 |
| KR20180097751A (ko) | 2018-08-31 |
| US20190016750A1 (en) | 2019-01-17 |
| EA036421B1 (ru) | 2020-11-09 |
| US10604542B2 (en) | 2020-03-31 |
| US20210147467A1 (en) | 2021-05-20 |
| CA3011528A1 (en) | 2017-07-20 |
| US10961270B2 (en) | 2021-03-30 |
| EP3402801A1 (en) | 2018-11-21 |
| PE20181330A1 (es) | 2018-08-20 |
| JP2019501204A (ja) | 2019-01-17 |
| CN109451740B (zh) | 2022-09-02 |
| AU2017207757B2 (en) | 2021-05-27 |
| AU2017207757A1 (en) | 2018-08-23 |
| US11505571B2 (en) | 2022-11-22 |
| WO2017123669A1 (en) | 2017-07-20 |
| CN109451740A (zh) | 2019-03-08 |
| EA201891565A1 (ru) | 2019-01-31 |
| MX2018008266A (es) | 2019-01-31 |
| JP6867395B2 (ja) | 2021-04-28 |
| CL2018001870A1 (es) | 2018-11-30 |
| MY194058A (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |